Ozagrel Sodium for Injection

[Pharmacology and Toxicology] This product is a thromboxane synthetase inhibitor, which can inhibit the production of TXA2, and thus has anti-platelet aggregation and vasodilation effects. Animal experiments show that intravenous administration can reduce plasma TXB2 levels, the Keto-PGF12/TXB2 ratio decreases, and has an inhibitory effect on platelet aggregation caused by different inducers, and has a preventive effect on cerebral infarction caused by the middle cerebral artery in rats. [Pharmacokinetics] After intravenous infusion of this product, the blood drug concentration-time curve conforms to the two-compartment open model, T1/2β is 1.22±0.44h, Vd is 2.32±0.62l/kg, and AUC is 0.47±0.08μg·hr/nl. Cl is 3.25±0.82l/h/kg, the longest half-life of the subject is 1.93h, and the blood drug concentration can be measured 3h after discontinuation of the drug. Almost all the drugs are excreted from the body through urine 24h after discontinuation of the drug.

The main ingredient of this product is: Ozagrel sodium. Its chemical name is: trans-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-acrylate sodium.

This product is white loose freeze-dried block.

It is suitable for the treatment of acute thrombotic cerebral infarction and movement disorders associated with cerebral infarction.

Adults: 40mg~80mg (2~4 vials) at a time, 1~2 times a day, dissolved in 500ml of normal saline or 5% glucose solution, continuous intravenous drip, 2 weeks as a course of treatment.

Gastrointestinal reactions and allergic reactions, such as nausea, vomiting, urticaria, rash, etc., are relieved after appropriate treatment. A few cases may experience increased GPT and BUN, intracranial, gastrointestinal, subcutaneous bleeding, and thrombocytopenia.

The following conditions are contraindicated: 1. Patients with hemorrhagic cerebral infarction or deep coma due to large-area cerebral infarction. 2. Patients with severe heart, lung, liver, and kidney dysfunction, such as severe arrhythmia and myocardial infarction. 3. Patients with blood diseases or bleeding tendency. 4. Patients with severe hypertension, systolic blood pressure exceeding 26.6kpa (i.e., more than 200 mmHg). 5. Patients who are allergic to this product.

Avoid mixing with calcium-containing infusions.

Keep away from light and store in a sealed container.

40mg (calculated as ozagrel sodium)

Harbin Medisan Pharmaceutical Co., Ltd.

• Founded in:

  1996-06-21

• Address:

  Beijing Road, Limin Development Zone, Harbin

• Tax NO.:

  91230100607168790X

• Registered Funds:

  316.35755 million yuan

• Website:

  Log in to view

• Email:

  Log in to view